No longer trading

Acquired by Alkermes plc

The acquisition closed on February 12, 2026 (SEC 8-K 2.01). Its last closing price was on February 11, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. Source: SEC 8-K 2.01

AVDL

AVADEL PHARMACEUTICALS PLC AVDL

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

Final 13F Pro quality score

Final rank #1,059 of 2,856 · as of July 1, 2026TOP 50%

Why it scores 57Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$77.47M

Quarter to Sep 30

Net income

$20.0K

Quarter to Sep 30

Free cash flow

$22.20M

Quarter to Sep 30

Operating margin

2.5%

Quarter to Sep 30

Top Institutional Holders

as of Q2 2026
$16 total
HUNTINGTON NATIONAL BANK
$160.0%
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2025
EDGAR

Net Income

Q3 2025
EDGAR

EPS (Diluted)

Q3 2025
EDGAR

Operating Margin

Q3 2025
EDGAR

ROIC

Q3 2025
EDGAR

Free Cash Flow

Q3 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AVDL

Earnings Per Share

13fpro.ai/company/AVDL

Loading ratio trend…

AVDL key financials by period

Reported revenue, net income and operating margin by fiscal year, from AVADEL PHARMACEUTICALS PLC's annual filings on SEC EDGAR.

AVADEL PHARMACEUTICALS PLC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$169.1M$-48.8M-25.1%
FY 2023$28.0M$-160.3M—
FY 2020$22.3M$7.0M26.0%
FY 2019$59.2M$-33.2M-40.7%
FY 2018$103.3M$-95.3M-101.6%
FY 2017$173.2M$68.3M51.7%
Source: AVDL filings on SEC EDGAR →

AVDL insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About AVADEL PHARMACEUTICALS PLC (AVDL): stock profile, AI score and financials

Acquired by Alkermes plc: AVADEL PHARMACEUTICALS PLC (AVDL) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on February 12, 2026 (SEC 8-K 2.01). Its last closing price was on February 11, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. AVADEL PHARMACEUTICALS PLC (AVDL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks AVDL using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q3 2025), AVADEL PHARMACEUTICALS PLC reports quarterly revenue of $77.5M, net income of $20.0K, an operating margin of 2.5%. AVDL trades on the Nasdaq exchange and files with the SEC under CIK 1012477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVADEL PHARMACEUTICALS PLC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1012477 →